On October 17, 2025 IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company focused on developing non-viral DNA-mediated immunotherapies and evaluating an adaptation of the platform’s potential as a next-generation vaccine, reported that members of its leadership team will deliver oral presentations highlighting IMNN-101, its investigational DNA plasmid vaccine based on the Company’s proprietary PlaCCine technology platform, including proof-of-concept clinical trial results at the following upcoming vaccine conferences:
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
5th Edition of International Vaccines Congress (IVC)
Keynote Oral Presentation Title: A promising novel approach to DNA vaccines
Presenting Author: Khursheed Anwer, Ph.D., M.B.A., Executive Vice President and Chief Science Officer, IMUNON, and IVC Scientific Committee Member
Date and Time: Thursday, October 23, 2025, 10:20 a.m. ET
Location: Orlando, Florida
10th International Conference on Vaccine Research and Development
Oral Presentation Title: Development of a PlaCCine DNA Technology for Safe, Effective and Durable Vaccines
Presenting Author: Douglas V. Faller, M.D., Ph.D., Chief Medical Officer, IMUNON
Date and Time: Thursday, November 6, 2025, 1:50 p.m. ET
Location: Boston, Massachusetts
In May 2025, IMUNON announced positive six-month data from the Phase 1 trial of IMNN-101 showing proof of concept of the PlaCCine technology, demonstrating better durability of protection compared to mRNA vaccines after a single dose targeting the SARS-CoV-2 Omicron XBB1.5 spike antigen variant. Results also showed IMNN-101 induced up to a 3-fold median increase in the serum neutralizing antibody (NAb) titers from baseline at six months, with initial evidence of a stronger immune response in the two higher dose cohorts (2.0 mg and 1.0 mg) compared to the lower dose cohort (0.5 mg). IMNN-101 was shown to be safe and well tolerated, with no serious adverse effects reported.
To accelerate the development and commercialization of the PlaCCine platform, IMUNON is actively seeking strategic partnerships with leading pharmaceutical and biotechnology companies. These collaborations aim to leverage PlaCCine’s unique advantages—enhanced durability, temperature stability, and scalable manufacturing—to address unmet needs in vaccines for infectious diseases and cancer, while securing non-dilutive funding to advance IMUNON’s broader oncology focused pipeline.
(Press release, IMUNON, OCT 17, 2025, View Source [SID1234656733])